

Appendix

Potential target patient populations 2022



Oncology

Hemophilia A


Ophthalmology

Neuroscience

Immunology

Herceptin + Perjeta, Phesgo

HER2+ early Breast Cancer (eBC)




Source: Roche/Genentech

Perjeta, Kadcyła

HER2+ metastatic Breast Cancer (mBC)

(thousands)




	HER2+ Rx opportunities		
	EU	US	China
1L ¹	9,096	9,918	34,293
2L	7,847	6,418	26,120
3L	5,694	3,897	13,610
4L+	3,381	1,620	5,798

Source: Roche/Genentech; ¹ de novo + adjuvant relapse

Giredestrant

HR+ BC

(thousands)




Source: Roche/Genentech

Tecentriq

Triple Negative Breast Cancer (TNBC)


(thousands)



Source: Roche/Genentech

Tecentriq, Tiragolumab

Non Squamous Non-Small Cell Lung Cancer (NSq NSCLC)




Source: Roche/Genentech

Alecensa


ALK+ Non-Small Cell Lung Cancer (NSCLC)

(thousands)



Rozlytrek (ROS1+), Gavreto (RET+)

ROS1 + and RET+ metastatic Non-Small Cell Lung Cancer (mNSCLC)




Source: Roche/Genentech

GDC-6036

KRAS G12C Non-Small Cell Lung Cancer (NSCLC)

(thousands)




Tecentriq

Small Cell Lung Cancer (SCLC)

(thousands)

2022 estimates for number of patients




Source: Roche/Genentech; ¹does not include recurrent

Tecentriq

Adjuvant Squamous Cell Carcinoma of the Head and Neck (SCCHN)

(thousands)




Source: Roche/Genentech

Tecentriq

Hepatic Cell Carcinoma (HCC)


(thousands)



Tiragolumab ESCC


(thousands)

2022 estimates for number of patients




Gazyva, Rituxan, Lunsumio, glofitabmab

Indolent Non-Hodkin's Lymphoma (iNHL)



Polivy, Rituxan, Lunsumio, glofitmab


Aggressive Non-Hodgkin's Lymphoma (aNHL/DLBCL)



Source: Roche/Genentech


Gazyva, Venclexta, Rituxan

Chronic Lymphocytic Leukemia (CLL)



Venclexta

Acute Myeloid Leukemia (AML)




Source: Roche/Genentech; Venclexta in collaboration with AbbVie

Venclexta, Cevostamab

Multiple Myeloma (MM)

(thousands)



Source: Roche/Genentech; Venclexta in collaboration with AbbVie



Oncology

Hemophilia A


Ophthalmology

Neuroscience

Immunology

Hemlibra

Hemophilia A





Oncology

Hemophilia A


Ophthalmology

Neuroscience

Immunology


Vabysmo, Susvimo, Lucentis

Neovascular Age-related Macular Degeneration (nAMD)




Vabysmo, Susvimo, Lucentis

Diabetic Macular Edema (DME)



Vabysmo, Lucentis

Retinal Vein Occlusion (RVO)





Oncology

Hemophilia A


Ophthalmology

Neuroscience

Immunology

Ocrevus, fenebrutinib

Multiple Sclerosis (MS)




Source: Roche/Genentech

Evrysdi


Spinal Muscular Atrophy (SMA)

(thousands)




Gantenerumab , semorinemab

Alzheimer's Disease (AD)



SRP-9001


Duchenne's Muscular Dystrophy



Source: Roche/Genentech; SPR-9001 in collaboration with Sarepta


Enspryng

Neuromyelitis Optica Spectrum Disorder (NMOSD)



Prasinezumab (RG7935)


Parkinson's Disease (PD)



Source: Roche/Genentech

Crovalimab

Paroxysmal Nocturnal Hemoglobinuria (PNH)





Oncology

Hemophilia A


Ophthalmology

Neuroscience


Immunology

Pentraxin-2, Esbriet

Idiopathic Pulmonary Fibrosis (IPF)




Diagnosed Prevalence by Severity



Xolair

Moderate to severe Asthma


(thousands)



Source: Roche/Genentech

Xolair


Chronic idiopathic urticarial (CIU)



Source: Roche/Genentech


Actemra, Rituxan

Rheumatoid Arthritis (RA)



Gazyva

Lupus Nephritis (LN)



Source: Roche/Genentech

Doing now what patients need next